Indicated for the prevention of disease caused by hepatitis A virus in person is 12 months of age and older.
The primary dose should be given at least two weeks prior to expected exposure to hepatitis A virus.
Essentially all recipients develop neutralizing antibodies.
Less effective in patients with transplant recipients, immunocompromised patients and patients with chronic liver disease.
Approved for children over the age of 2 years.
Effective for postexposure prophylaxis.